Public source
Reviewed 4 Jun 2026
Completeness Good (44%)
EIDOS (phased out)
Ellogon.AIEIDOS is an AI-based solution that assists in predicting whether a patient will benefit from immunotherapy based on digitized histopathology slides.
No papers to support — we monitor for new evidence.
Key features
Immunotherapy indication
General Information
Product name
Company
Modality
Main task
Subspeciality
Organ/Specimen source
Not specified
Disease targeted
Specimen type
Not specified
Staining
Not specified
Stain subtype
Not specified
Regulatory Information
Pathway:
In Vitro Diagnostic Directive (IVDD)
Class:
General IVD Devices
Not verified by Health AI Register
Scanner Brands Certified for Use (CE-IVD)
Not specified
Scanner Models Certified for Use (CE-IVD)
Not specified
Other certifications
Not specified
Evidence & Research
No research papers or evidence on file yet.
The registry monitors publications for new evidence.
Technical Specifications
Patient population age
Not specified
Input
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Trigger for analysis
Not specified
Processing time
Population
Not specified
Viewer systems
Not specified
Market Presence
On market since
AI Platforms
Resellers
Not specified
Countries present
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Source: Public | First published: Aug 1, 2025 | Last updated: Jun 4, 2026